查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1806514

液態切片市場按生物標記、樣本、類型、技術、適應症、最終用戶和應用分類——2025-2030 年全球預測

Liquid Biopsy Market by Biomarkers, Sample, Type, Technology, Indication, End-User, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計液態切片市場規模到 2024 年將達到 67.2 億美元，到 2025 年將達到 75.2 億美元，複合年成長率為 12.24%，到 2030 年將達到 134.4 億美元。

主要市場統計數據
基準年2024年 67.2億美元
預計2025年 75.2億美元
預測年份 2030 134.4億美元
複合年成長率（%） 12.24%

為行業相關人員提供關於液態切片及其在精準醫療和腫瘤診斷中的變革潛力的權威介紹

液態切片代表了診斷醫學的模式轉移，透過分析體液中的循環生物標記物，為腫瘤生物學研究提供了一個微創的窗口。與需要手術切除且有操作風險的傳統組織切片檢查不同，液態切片利用循環腫瘤DNA、細胞和囊泡來即時捕獲動態分子資訊。這種方法與日益受到重視的精準腫瘤學相契合，精準腫瘤學可以透過根據個別分子譜量身訂做治療方法來顯著改善患者預後。

透過技術突破、監管發展和策略產業合作，探索重新定義液態切片的關鍵變化

在次世代定序儀、數位PCR和新型生物資訊流程的突破推動下，液態切片領域正以前所未有的速度發展。這些技術進步顯著提高了分析物檢測的敏感度和特異性，使得在癌症早期階段就能辨識出稀有的循環腫瘤DNA片段。同時，主要市場的監管機構已開始宣布更簡化的伴隨診斷核准途徑，反映出人們對其臨床效用和可重複性的信心。

評估 2025 年美國關稅對液態切片供應鏈定價結構和國際研究合作的累積影響

美國對進口診斷劑和設備徵收的新關稅於2025年1月1日生效，這為跨境供應鏈帶來了新的複雜性。額外的關稅增加了關鍵耗材的到岸成本，迫使製造商和實驗室合作夥伴重新評估籌資策略和庫存模式。對於依賴專用試劑的公司來說，尋找替代的國內供應商或談判長期合約已成為維持微薄利潤和避免服務中斷的關鍵目標。

從生物標記樣本、檢測類型、技術、適應症和最終用戶動態的多方面細分中獲得關鍵見解

依生物標記類別細分可揭示成熟分析物和新興分析物之間的相互作用。由於遊離DNA與腫瘤負荷和突變譜具有明確的相關性，因此它在臨床檢測中繼續發揮核心作用，而循環性腫瘤細胞則為表現型分析釋放了機會。循環腫瘤DNA技術的出現使得即時監測抗藥性突變成為可能，而對細胞外囊泡的探索則開闢了圍繞RNA貨物和蛋白質組學特徵的新研究前沿。

揭示影響液態切片應用和創新的區域動態：美洲、中東和非洲以及亞太地區

美洲憑藉先進的法律規範和大規模臨床應用繼續保持領先地位。政府推出的以癌症篩檢和價值導向醫療為重點的舉措正在加速報銷討論，並推動其在學術醫療中心和社區醫院的廣泛應用。此外，本地診斷公司與國際技術供應商之間的策略聯盟正在強化供應鏈，並擴大該地區獲得尖端檢測方法的管道。

快速發展的液態切片生態系統中主要企業的策略定位。競爭優勢和市場貢獻分析。

領先的診斷和生物技術公司正透過差異化平台、策略性收購和廣泛的智慧財產權組合來定位自身。擁有成熟實驗室網路的傳統公司正在利用深度臨床檢驗數據來擴展其檢測菜單，而純粹的創新公司則透過專注於專有化學和先進的生物資訊學來搶佔早期市場准入。

為行業相關人員制定前瞻性策略和實用建議，以利用液態切片領域的進步和市場機會

為了應對不斷變化的液態切片格局，行業相關人員應優先投資於支援靶向和廣泛應用的靈活體組織切片測架構。這種方法將有助於我們靈活應對新興生物標記和監管變化。將多體學功能整合到現有工作流程中，將提高診斷準確性，並提供更深入的腫瘤異質性洞察。

嚴格的調查方法概述，包括資料收集、分析和檢驗，全面涵蓋液態切片領域

本報告的調查方法嚴格結合二手資料和一手資料，以確保報告的穩健性和可靠性。首先，我們進行了廣泛的二手資料研究，涵蓋同行評審期刊、臨床試驗註冊中心、專利申請、監管出版物、白皮書等，以建立全面的技術和臨床理解基礎。

摘要液態切片創新為精準診斷和患者照護進步帶來的策略意義、未來前景和持久價值

液態切片已成為現代診斷實踐的基石，彌合了分子診斷與個人化患者管理之間的差距。透過實現疾病檢測和監測的非侵入性採樣，液態切片正在為早期療育、治療最佳化和縱向監測開闢新的途徑。隨著技術平台的成熟，液態切片正從小眾研究應用走向主流臨床實踐。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章市場動態

  • 採用超靈敏數位PCR技術進行腫瘤微量殘存疾病監測
  • 透過整合 ctDNA 甲基化和蛋白質生物標記的多體學檢測進行早期疾病篩檢
  • 分散式照護現場平台的出現，使得在家中快速監測癌症成為可能
  • 利用人工智慧驅動的演算法全面解讀循環性腫瘤細胞異質性
  • 透過細胞外DNA碎片分析篩檢胎兒非整倍體和微缺失，擴大非侵入性產前檢測
  • 診斷開發商與製藥公司建立策略聯盟，加速生物標記發現並伴隨診斷開發

第6章 市場洞察

  • 波特五力分析
  • PESTEL分析

第7章 2025年美國關稅的累積影響

第 8 章液態切片市場（按生物標記）

  • 遊離DNA
  • 循環性腫瘤細胞
  • 循環腫瘤DNA
  • 細胞外囊泡

第9章液態切片市場（按樣本）

  • 以血液為基礎
  • 尿基

第 10 章液態切片市場（按類型）

  • 檢測試劑套件
  • 裝置
  • 服務

第 11 章液態切片市場（按技術）

  • 使用NGS並行分析多個基因
  • 使用PCR微陣列進行單一基因分析

第 12 章液態切片市場（按適應症）

  • 癌症適應症
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 黑色素瘤
    • 攝護腺癌
  • 非癌症適應症

第 13 章液態切片市場（按最終用戶）

  • 學術研究中心
  • 臨床診斷實驗室
  • 醫院
  • 醫生辦公室檢查室

第14章液態切片市場（按應用）

  • 早期癌症篩檢
  • 復發監測
  • 治療方法方案
  • 治療監測

15. 美國液態切片市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

16. 歐洲、中東和非洲液態切片市場

  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 阿拉伯聯合大公國
  • 沙烏地阿拉伯
  • 南非
  • 丹麥
  • 荷蘭
  • 卡達
  • 芬蘭
  • 瑞典
  • 奈及利亞
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波蘭
  • 瑞士

17. 亞太液態切片市場

  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國
  • 印尼
  • 泰國
  • 菲律賓
  • 馬來西亞
  • 新加坡
  • 越南
  • 台灣

第18章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Illumina, Inc.
    • Labcorp Holdings Inc.
    • ANGLE PLC
    • Bio-Rad Laboratories, Inc.
    • Bio-Techne Corporation
    • Biocartis NV
    • Danaher Corporation
    • DiaCarta, Inc.
    • Dxcover Limited
    • Epic Sciences Inc.
    • Exact Sciences Corporation
    • F. Hoffmann-La Roche Ltd.
    • GENCURIX
    • Guardant Health, Inc.
    • Laboratory Dr. med. Pachmann
    • Lucence Health Inc.
    • LungLife AI, Inc.
    • MDxHealth SA
    • Menarini Silicon Biosystems SpA
    • Merck KGaA
    • Myriad Genetics, Inc.
    • Natera, Inc.
    • NeoGenomics Laboratories, Inc.
    • OncoDNA SA
    • PerkinElmer, Inc.
    • Personalis, Inc.
    • QIAGEN NV
    • SAGA Diagnostics AB
    • Strand Life Sciences Pvt Ltd.
    • Sysmex Corporation
    • Tempus AI, Inc.
    • Thermo Fisher Scientific Inc.

第19章 研究人工智慧

第20章 研究統計

第21章 研究聯絡人

第22章 研究報導

第23章 附錄

Product Code: MRR-43470FC608C8

The Liquid Biopsy Market was valued at USD 6.72 billion in 2024 and is projected to grow to USD 7.52 billion in 2025, with a CAGR of 12.24%, reaching USD 13.44 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 6.72 billion
Estimated Year [2025] USD 7.52 billion
Forecast Year [2030] USD 13.44 billion
CAGR (%) 12.24%

An authoritative introduction to liquid biopsy and its transformative potential in precision medicine and oncology diagnostics for industry stakeholders

Liquid biopsy represents a paradigm shift in diagnostic medicine by offering a minimally invasive window into tumor biology through the analysis of circulating biomarkers in bodily fluids. Unlike conventional tissue biopsies that necessitate surgical extraction and carry procedural risks, liquid biopsy harnesses circulating tumor DNA, cells, and vesicles to capture dynamic molecular information in real time. This approach aligns with the growing emphasis on precision oncology, where tailoring therapeutic regimens to individual molecular profiles can dramatically improve patient outcomes.

As cancer incidence continues to rise globally, healthcare systems are under pressure to deliver cost-effective, rapid diagnostics that minimize patient discomfort without compromising accuracy. Liquid biopsy addresses these demands by enabling serial monitoring of disease progression, early detection of minimal residual disease, and the identification of actionable mutations that guide targeted therapies. Moreover, its application extends beyond oncology into transplant medicine, prenatal screening, and infectious disease monitoring, positioning liquid biopsy as a versatile tool for modern clinical practice.

Stakeholders across pharmaceutical, diagnostic, and research sectors are now evaluating how to integrate liquid biopsy into existing workflows and regulatory pathways. With technological advances driving down assay time and costs, liquid biopsy is poised to become a standard component of patient management. In the following sections, we explore the transformative forces reshaping this landscape, the implications of recent policy changes, and the strategic insights that will guide industry leaders forward.

Exploring the pivotal shifts redefining the liquid biopsy landscape through technological breakthroughs regulatory progress and strategic industry collaborations

The liquid biopsy landscape is evolving at an unprecedented pace, propelled by breakthroughs in next-generation sequencing, digital PCR, and novel bioinformatics pipelines. These technological advancements have significantly increased the sensitivity and specificity of analyte detection, enabling the identification of rare circulating tumor DNA fragments at early stages of cancer. Concurrently, regulatory agencies across key markets have begun to issue more streamlined approval pathways for companion diagnostics, reflecting confidence in the clinical utility and reproducibility of liquid biopsy assays.

At the same time, strategic collaborations between diagnostic manufacturers, academic centers, and pharmaceutical firms are accelerating assay validation and broadening the scope of clinical studies. Such partnerships are fostering the co-development of targeted panels aligned with emerging targeted therapies, thereby integrating diagnostics directly into the drug development lifecycle. Meanwhile, decentralized testing models-ranging from point-of-care platforms to patient-collected sampling kits-are democratizing access and supporting remote monitoring initiatives.

Collectively, these forces are redefining the competitive dynamics of the liquid biopsy domain. Incumbent laboratory providers are investing in proprietary platforms to maintain differentiation, while nimble start-ups continue to innovate assay chemistries and data analytics. Looking ahead, convergence around multi-omics integration and standardized reporting frameworks will further solidify liquid biopsy's role as a cornerstone of personalized care.

Assessing the cumulative repercussions of the 2025 United States tariffs on liquid biopsy supply chains pricing structures and global research collaborations

On January 1, 2025, new U.S. tariffs on imported diagnostic reagents and instrumentation took effect, introducing a layer of complexity for cross-border supply chains. The added duties have increased landed costs for core consumables, prompting manufacturers and laboratory partners to reassess sourcing strategies and inventory models. For companies reliant on specialized reagents, securing alternative domestic suppliers or negotiating long-term contracts has become a critical objective to contain margins and avoid service disruptions.

The ripple effects extend into pricing structures, as laboratories pass incremental expenses to payers and patients, potentially impacting adoption rates in price-sensitive segments. To mitigate these pressures, several industry players have begun exploring localized manufacturing solutions, including establishing regional production hubs and partnering with contract development organizations. In parallel, increased collaboration with customs authorities and trade associations has enabled more efficient classification and duty minimization, offering relief to stakeholders navigating the evolving tariff landscape.

Despite these headwinds, many organizations view the 2025 tariffs as a catalyst to strengthen domestic supply resilience and foster innovation in reagent design. By investing in robust regional capabilities and diversifying supplier networks, the industry anticipates a more balanced cost structure over the long term, ultimately supporting sustainable growth and uninterrupted patient access.

Deriving critical insights from multifaceted segmentation of biomarkers samples assay types technologies indications applications and end-user dynamics

Segmentation by biomarker class reveals the interplay between mature and emerging analytes. Cell-free DNA continues to anchor clinical assays due to its well-established correlation with tumor burden and mutational profiling, while circulating tumor cells unlock opportunities for phenotypic analysis. The advent of circulating tumor DNA technologies enables real-time monitoring of resistance mutations, and the exploration of extracellular vesicles is opening new research frontiers around RNA cargo and proteomic signatures.

When considering sample origin, blood-based tests dominate current workflows because of established venipuncture protocols and high analyte yield. However, urine-based assays are gaining traction as a noninvasive alternative for longitudinal screening, particularly in urological and genitourinary indications. Advances in sample stabilization and extraction methods are narrowing performance gaps, setting the stage for wider clinical adoption of diversified fluid matrices.

In terms of product taxonomy, assay kits form the backbone of commercial offerings by delivering standardized workflows that simplify laboratory implementation. Instruments add value through automation and throughput optimization, while services encompass bespoke assay development, data interpretation, and clinical reporting. On the technology front, multi-gene parallel analysis using next-generation sequencing is prized for its multiplexing capacity and depth of coverage, whereas single-gene analysis via PCR microarrays maintains a strong presence in targeted mutation detection due to rapid turnaround.

Indication-driven segmentation underscores the primacy of cancer applications, with breast, colorectal, lung, melanoma, and prostate cancers accounting for the majority of clinical validation studies. Non-cancer indications are expanding into areas such as organ transplant rejection monitoring and prenatal aneuploidy screening. Among end-users, academic and research centers spearhead exploratory studies, while clinical diagnostic laboratories, hospitals, and physician office labs drive routine testing volumes. Finally, application segmentation reveals a balanced portfolio of early cancer screening initiatives, recurrence monitoring protocols, therapy selection assays, and treatment monitoring programs, reflecting the multifaceted utility of liquid biopsy in patient management.

Uncovering regional dynamics shaping liquid biopsy adoption and innovation across the Americas Europe Middle East Africa and Asia Pacific markets

The Americas continue to lead with advanced regulatory frameworks and high-volume clinical adoption. Government initiatives focusing on cancer screening and value-based care have accelerated reimbursement discussions, enabling broader uptake in both academic medical centers and community hospitals. Moreover, strategic partnerships between local diagnostic companies and international technology providers have fortified supply chains and expanded regional access to cutting-edge assays.

Europe, Middle East, and Africa present a heterogeneous landscape marked by diverse regulatory regimes and reimbursement environments. In Western Europe, centralized health technology assessments and national screening programs drive standardization, whereas emerging markets in Eastern Europe, the Middle East, and Africa are gradually integrating liquid biopsy into oncology networks through pilot projects and center-of-excellence collaborations. Cross-border data sharing and harmonized clinical guidelines remain key enablers of sustainable growth across these jurisdictions.

Asia-Pacific is characterized by rapid market expansion underpinned by significant public health investments and rising cancer incidence. Government funding for cancer genomics and domestic manufacturing incentives have catalyzed indigenous assay development. Collaborative research between regional academic institutions and global diagnostic firms is intensifying, while the rollout of digital pathology and telemedicine platforms supports remote sample collection and result dissemination, extending the reach of liquid biopsy solutions.

Analyzing strategic positioning competitive strengths and market contributions of leading corporations in the rapidly evolving liquid biopsy ecosystem

Leading diagnostic and biotechnology companies are positioning themselves through differentiated platforms, strategic acquisitions, and expansive intellectual property portfolios. Legacy players with established laboratory networks are leveraging deep clinical validation data to extend their assay menus, while pure-play innovators focus on proprietary chemistries and advanced bioinformatics to achieve early market entry.

Collaborative alliances between pharmaceutical companies and diagnostic developers are accelerating the co-development of companion diagnostics tailored to specific targeted therapies. Start-ups are forging partnerships with contract research organizations to streamline multicenter clinical trials, ensuring robust evidence generation and regulatory alignment. At the same time, instrument manufacturers are integrating connectivity features and cloud-based data analytics into their platforms, enhancing operational efficiency and facilitating seamless integration with laboratory information systems.

Beyond technology differentiation, corporate strategies are increasingly oriented toward geographic expansion through regional sales networks and production hubs. By aligning global R&D pipelines with localized commercialization strategies, leading companies are building scalable models that address diverse regulatory requirements and market access challenges.

Crafting forward-looking strategies and practical recommendations for industry stakeholders to capitalize on liquid biopsy advancements and market opportunities

To navigate the evolving liquid biopsy environment, industry stakeholders should prioritize investment in flexible assay architectures that support both targeted and broad-panel applications. This approach ensures agility in responding to emerging biomarkers and regulatory shifts. Integrating multi-omics capabilities into existing workflows will enhance diagnostic accuracy and provide richer insights into tumor heterogeneity.

Building resilient supply chains through regional manufacturing partnerships and dual-sourcing agreements can mitigate exposure to trade policy fluctuations. Organizations should also establish cross-functional teams that unite regulatory, commercial, and scientific experts to streamline product approvals and reimbursement negotiations. Collaborative initiatives with payers and healthcare providers will strengthen the value proposition by demonstrating real-world clinical utility and cost savings.

Digital transformation should remain a strategic priority, with investments in cloud-native analytics, artificial intelligence-driven variant interpretation, and telehealth-enabled sample collection. These technologies will support decentralized testing models and personalized patient engagement. Finally, fostering open innovation through consortiums and public-private partnerships will accelerate the validation of novel analytes and drive the harmonization of reporting standards, reinforcing liquid biopsy's role in precision medicine.

Outlining rigorous research methodology encompassing data collection analysis validation to ensure comprehensive coverage of the liquid biopsy domain

This report's methodology integrates a rigorous blend of secondary and primary research to ensure robustness and credibility. Initially, extensive secondary research was conducted, encompassing peer-reviewed journals, clinical trial registries, patent filings, regulatory publications, and white papers to establish a comprehensive foundation of technical and clinical understanding.

Primary research was conducted through in-depth interviews with senior executives, laboratory directors, and key opinion leaders across diagnostics, pharmaceutical, and academic sectors. These expert dialogues provided nuanced perspectives on assay development, regulatory strategy, and commercialization challenges. Data triangulation techniques validated qualitative insights against proprietary databases and financial disclosures to reinforce accuracy.

Quantitative analysis involved mapping product pipelines, technology adoption metrics, and regional deployment patterns. Key variables were cross-referenced with public health statistics and reimbursement schedules to contextualize application potential. Validation workshops with external advisors and technical specialists were organized to resolve discrepancies and refine assumptions.

Collectively, this multi-layered approach delivers a holistic view of the liquid biopsy domain, balancing empirical evidence with expert interpretation to guide strategic decision-making.

Summarizing the strategic significance future outlook and enduring value of liquid biopsy innovations for advancing precision diagnostics and patient care

Liquid biopsy has emerged as a cornerstone of modern diagnostic practice, bridging the gap between molecular insights and personalized patient management. Its capacity to detect and monitor disease through noninvasive sampling unlocks new avenues for early intervention, treatment optimization, and long-term surveillance. As technology platforms mature, liquid biopsy is transitioning from niche research applications to mainstream clinical adoption.

Strategically, stakeholders who align their portfolios with the evolving landscape-incorporating flexible assay designs, resilient supply chains, and digital innovation-will be best positioned to capitalize on market opportunities. Continued collaboration across industry, academia, and regulatory bodies will drive the standardization of workflows and reimbursement frameworks, further reducing barriers to implementation.

Looking ahead, the integration of liquid biopsy with complementary diagnostics and therapeutic modalities promises to accelerate the shift toward truly individualized medicine. By embracing a data-driven, patient-centered approach, industry leaders can unlock significant clinical and commercial value, reinforcing liquid biopsy's role as a transformative force in healthcare.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Adoption of ultra-high sensitivity digital PCR techniques for minimal residual disease monitoring in oncology
  • 5.2. Integration of multi-omic liquid biopsy assays combining ctDNA methylation and protein biomarkers for early disease screening
  • 5.3. Emergence of decentralized point-of-care liquid biopsy platforms enabling rapid at-home cancer monitoring
  • 5.4. Use of artificial intelligence-driven algorithms for comprehensive interpretation of circulating tumor cell heterogeneity
  • 5.5. Expansion of noninvasive prenatal testing with fetal aneuploidy and microdeletion screening through cell-free DNA fragmentation analysis
  • 5.6. Strategic collaborations between diagnostic developers and pharmaceutical companies to accelerate biomarker discovery and companion diagnostic development

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Liquid Biopsy Market, by Biomarkers

  • 8.1. Introduction
  • 8.2. Cell-free DNA
  • 8.3. Circulating Tumor Cells
  • 8.4. Circulating Tumor DNA
  • 8.5. Extracellular Vesicles

9. Liquid Biopsy Market, by Sample

  • 9.1. Introduction
  • 9.2. Blood Based
  • 9.3. Urine Based

10. Liquid Biopsy Market, by Type

  • 10.1. Introduction
  • 10.2. Assay Kits
  • 10.3. Instruments
  • 10.4. Services

11. Liquid Biopsy Market, by Technology

  • 11.1. Introduction
  • 11.2. Multi-gene Parallel Analysis using NGS
  • 11.3. Single-gene Analysis using PCR Microarrays

12. Liquid Biopsy Market, by Indication

  • 12.1. Introduction
  • 12.2. Cancer Indication
    • 12.2.1. Breast Cancer
    • 12.2.2. Colorectal Cancer
    • 12.2.3. Lung Cancer
    • 12.2.4. Melanoma
    • 12.2.5. Prostate Cancer
  • 12.3. Non-Cancer Indication

13. Liquid Biopsy Market, by End-User

  • 13.1. Introduction
  • 13.2. Academic & Research Centers
  • 13.3. Clinical Diagnostic Laboratories
  • 13.4. Hospitals
  • 13.5. Physician's Office Laboratories

14. Liquid Biopsy Market, by Application

  • 14.1. Introduction
  • 14.2. Early Cancer Screening
  • 14.3. Recurrence Monitoring
  • 14.4. Therapy Selection
  • 14.5. Treatment Monitoring

15. Americas Liquid Biopsy Market

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. Argentina

16. Europe, Middle East & Africa Liquid Biopsy Market

  • 16.1. Introduction
  • 16.2. United Kingdom
  • 16.3. Germany
  • 16.4. France
  • 16.5. Russia
  • 16.6. Italy
  • 16.7. Spain
  • 16.8. United Arab Emirates
  • 16.9. Saudi Arabia
  • 16.10. South Africa
  • 16.11. Denmark
  • 16.12. Netherlands
  • 16.13. Qatar
  • 16.14. Finland
  • 16.15. Sweden
  • 16.16. Nigeria
  • 16.17. Egypt
  • 16.18. Turkey
  • 16.19. Israel
  • 16.20. Norway
  • 16.21. Poland
  • 16.22. Switzerland

17. Asia-Pacific Liquid Biopsy Market

  • 17.1. Introduction
  • 17.2. China
  • 17.3. India
  • 17.4. Japan
  • 17.5. Australia
  • 17.6. South Korea
  • 17.7. Indonesia
  • 17.8. Thailand
  • 17.9. Philippines
  • 17.10. Malaysia
  • 17.11. Singapore
  • 17.12. Vietnam
  • 17.13. Taiwan

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. Illumina, Inc.
    • 18.3.2. Labcorp Holdings Inc.
    • 18.3.3. ANGLE PLC
    • 18.3.4. Bio-Rad Laboratories, Inc.
    • 18.3.5. Bio-Techne Corporation
    • 18.3.6. Biocartis NV
    • 18.3.7. Danaher Corporation
    • 18.3.8. DiaCarta, Inc.
    • 18.3.9. Dxcover Limited
    • 18.3.10. Epic Sciences Inc.
    • 18.3.11. Exact Sciences Corporation
    • 18.3.12. F. Hoffmann-La Roche Ltd.
    • 18.3.13. GENCURIX
    • 18.3.14. Guardant Health, Inc.
    • 18.3.15. Laboratory Dr. med. Pachmann
    • 18.3.16. Lucence Health Inc.
    • 18.3.17. LungLife AI, Inc.
    • 18.3.18. MDxHealth SA
    • 18.3.19. Menarini Silicon Biosystems SpA
    • 18.3.20. Merck KGaA
    • 18.3.21. Myriad Genetics, Inc.
    • 18.3.22. Natera, Inc.
    • 18.3.23. NeoGenomics Laboratories, Inc.
    • 18.3.24. OncoDNA SA
    • 18.3.25. PerkinElmer, Inc.
    • 18.3.26. Personalis, Inc.
    • 18.3.27. QIAGEN N.V.
    • 18.3.28. SAGA Diagnostics AB
    • 18.3.29. Strand Life Sciences Pvt Ltd.
    • 18.3.30. Sysmex Corporation
    • 18.3.31. Tempus AI, Inc.
    • 18.3.32. Thermo Fisher Scientific Inc.

19. ResearchAI

20. ResearchStatistics

21. ResearchContacts

22. ResearchArticles

23. Appendix

LIST OF FIGURES

  • FIGURE 1. LIQUID BIOPSY MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
  • FIGURE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 22. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 25. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 26. ASIA-PACIFIC LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 27. LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 29. LIQUID BIOPSY MARKET: RESEARCHAI
  • FIGURE 30. LIQUID BIOPSY MARKET: RESEARCHSTATISTICS
  • FIGURE 31. LIQUID BIOPSY MARKET: RESEARCHCONTACTS
  • FIGURE 32. LIQUID BIOPSY MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL LIQUID BIOPSY MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL LIQUID BIOPSY MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL LIQUID BIOPSY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BLOOD BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL LIQUID BIOPSY MARKET SIZE, BY URINE BASED, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INSTRUMENTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SERVICES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MULTI-GENE PARALLEL ANALYSIS USING NGS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL LIQUID BIOPSY MARKET SIZE, BY SINGLE-GENE ANALYSIS USING PCR MICROARRAYS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL LIQUID BIOPSY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL LIQUID BIOPSY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL LIQUID BIOPSY MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL LIQUID BIOPSY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL LIQUID BIOPSY MARKET SIZE, BY NON-CANCER INDICATION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL LIQUID BIOPSY MARKET SIZE, BY ACADEMIC & RESEARCH CENTERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL LIQUID BIOPSY MARKET SIZE, BY CLINICAL DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 63. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL LIQUID BIOPSY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 65. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL LIQUID BIOPSY MARKET SIZE, BY PHYSICIAN'S OFFICE LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 67. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 69. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL LIQUID BIOPSY MARKET SIZE, BY EARLY CANCER SCREENING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 71. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 73. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL LIQUID BIOPSY MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 75. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL LIQUID BIOPSY MARKET SIZE, BY TREATMENT MONITORING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 77. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 78. AMERICAS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 79. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 80. AMERICAS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 81. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 83. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 84. AMERICAS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 85. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 86. AMERICAS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 87. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 88. AMERICAS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 89. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 90. AMERICAS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 91. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 92. AMERICAS LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 93. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. AMERICAS LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 95. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 96. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 97. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 98. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 99. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 101. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 102. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 103. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 104. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 105. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 106. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 107. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 108. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 109. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 110. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 111. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 112. UNITED STATES LIQUID BIOPSY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 113. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 114. CANADA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 115. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 116. CANADA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 117. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. CANADA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 120. CANADA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 121. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 122. CANADA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 123. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 124. CANADA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 125. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 126. CANADA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 127. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 128. CANADA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 129. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 130. MEXICO LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 131. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 132. MEXICO LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 133. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 134. MEXICO LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 135. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 136. MEXICO LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 137. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 138. MEXICO LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 139. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 140. MEXICO LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 141. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 142. MEXICO LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 143. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 144. MEXICO LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 145. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 146. BRAZIL LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 147. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 148. BRAZIL LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 149. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 150. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 151. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 152. BRAZIL LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 153. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 154. BRAZIL LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 155. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 156. BRAZIL LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 157. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 158. BRAZIL LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 159. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 160. BRAZIL LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 161. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 162. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 163. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 164. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 165. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 167. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 169. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 170. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 171. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 172. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 173. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 174. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 175. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 176. ARGENTINA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 181. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 183. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 185. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 196. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 198. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 202. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 203. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 204. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 205. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 207. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 208. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 209. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 210. UNITED KINGDOM LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 211. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 212. GERMANY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 213. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 214. GERMANY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 215. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. GERMANY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 218. GERMANY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 219. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. GERMANY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 221. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 222. GERMANY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 223. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 224. GERMANY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 225. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 226. GERMANY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 227. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 228. FRANCE LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 229. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 230. FRANCE LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 231. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. FRANCE LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 234. FRANCE LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 235. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 236. FRANCE LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 237. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 238. FRANCE LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 239. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 240. FRANCE LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 241. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 242. FRANCE LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 243. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 244. RUSSIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 245. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 246. RUSSIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 247. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 250. RUSSIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 251. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 252. RUSSIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 253. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 254. RUSSIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 255. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 256. RUSSIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 257. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 258. RUSSIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 259. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 260. ITALY LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 261. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 262. ITALY LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 263. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. ITALY LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 266. ITALY LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 267. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 268. ITALY LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 269. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 270. ITALY LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 271. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 272. ITALY LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 273. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 274. ITALY LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 275. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 276. SPAIN LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 277. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 278. SPAIN LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 279. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. SPAIN LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 281. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. SPAIN LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 283. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 284. SPAIN LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 285. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 286. SPAIN LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 287. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 288. SPAIN LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 289. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 290. SPAIN LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 291. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 292. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 293. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 294. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 295. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 298. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 299. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 300. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 301. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 302. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 303. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 304. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 305. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 306. UNITED ARAB EMIRATES LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 307. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 308. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 309. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 310. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 311. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 312. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 314. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 316. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 318. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 320. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 321. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 322. SAUDI ARABIA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 324. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 326. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 328. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 329. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 330. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 331. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 332. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 333. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 334. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 336. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 338. SOUTH AFRICA LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 339. DENMARK LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 340. DENMARK LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 341. DENMARK LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 342. DENMARK LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 343. DENMARK LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 344. DENMARK LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 345. DENMARK LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 346. DENMARK LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 347. DENMARK LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 348. DENMARK LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 349. DENMARK LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 350. DENMARK LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 351. DENMARK LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 352. DENMARK LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 353. DENMARK LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
  • TABLE 354. DENMARK LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
  • TABLE 355. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2018-2024 (USD MILLION)
  • TABLE 356. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY BIOMARKERS, 2025-2030 (USD MILLION)
  • TABLE 357. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2018-2024 (USD MILLION)
  • TABLE 358. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY SAMPLE, 2025-2030 (USD MILLION)
  • TABLE 359. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2018-2024 (USD MILLION)
  • TABLE 360. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TYPE, 2025-2030 (USD MILLION)
  • TABLE 361. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 362. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 363. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 364. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
  • TABLE 365. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2018-2024 (USD MILLION)
  • TABLE 366. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY CANCER INDICATION, 2025-2030 (USD MILLION)
  • TABLE 367. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 368. NETHERLANDS LIQUID BIOPSY MARKET SIZE, BY END-USER, 2025-2